-
Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026
•
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from the US Food and Drug Administration (FDA) for its mRNA vaccine candidate, YKYY026, aimed at preventing herpes zoster. YKYY026: An Innovative mRNA Vaccine with Proprietary Delivery SystemYKYY026 is a novel mRNA vaccine that utilizes Youcare…
-
Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
•
Duality Biologics, in partnership with BioNTech (NASDAQ: BNTX), has announced the initial data from the global 1/2a phase clinical trial of its B7H3-targeting antibody-drug conjugate (ADC), DB-1311 (BNT324). The trial marks a significant advancement in the treatment of patients with locally advanced or metastatic solid tumors who have previously received…
-
Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced
•
China-based innovative drug company Chipscreen Biosciences (SHA: 688321) has announced the completion of the analysis of results from the Phase III clinical trial for its drug candidate chiauranib, used as a monotherapy for third-line and above small cell lung cancer (SCLC). The independent review committee (IRC) has assessed the trial’s…
-
Immunofoco’s IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer
•
Immunofoco, a biotechnology company specializing in immunotherapy, has announced that its self-developed autologous CAR-T product, IMC002, targeting CLDN 18.2, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). This designation is for the treatment of patients with unresectable locally advanced, recurrent, or metastatic CLDN…
-
Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial
•
Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation (CDE) has approved the first pivotal Phase II registration clinical trial for its GC101 TIL injection. The trial, designated as NCT06703398, is for the treatment of advanced melanoma patients who have progressed or are intolerant…
-
Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials
•
China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance from the US Food and Drug Administration (FDA) for its innovative drug candidate, Y-0301, a bispecific nanobody targeting MET and EGFR pathways. Y-0301: A Pioneering Bispecific NanobodyY-0301, the world’s first bispecific nanobody developed through Novatim’s…
-
HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors
•
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed that it has received tacit clinical approval from the National Medical Products Administration (NMPA) for its drug candidate HF50. This T-cell redirecting antibody fragment-anchored liposomes (TRAFsomes) product will be tested in clinical trials for HER-2…
-
Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment
•
The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang Hongqi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196). This approval marks a significant advancement in the treatment of drug-resistant tuberculosis (TB) patients. Innovative Mechanism of Action Pretomanid is…
-
Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received breakthrough therapy designation (BTD) from the National Medical Products Administration of China for its pipeline candidate, SHR-A2102. The designation is in recognition of the molecule’s potential in treating locally advanced or metastatic urothelial carcinoma in patients who…
-
Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for its drug Columvi (glofitamab). Roche is seeking FDA approval for the use of Columvi in combination with gemcitabine and oxaliplatin (GemOx) for the…
-
Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
•
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings in Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. to JKI, a company established by a fund managed and operated by J-Will. This strategic move aligns with Teva’s Pivot to…
-
Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment
•
US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma Corporation (MTPC) to enhance the development of Dewpoint’s novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS). This collaboration aims to address the mislocalization of the TAR DNA-binding protein 43 (TDP-43), a…
-
AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from the US Food and Drug Administration (FDA) for its programmed death-ligand 1 (PD-L1) inhibitor, Imfinzi (durvalumab). The approval is for the use of Imfinzi in treating adult patients with limited-stage small cell lung cancer (LS-SCLC)…
-
Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral
•
US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the Phase III MOVE-NOW study for its oral antiviral COVID-19 medicine, Lagevrio (molnupiravir), in adults with COVID-19 who are at high risk for disease progression. This trial marks a significant step in the ongoing development and…
-
CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
•
China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated that the Category 1 drug RG002, developed by Suzhou-based mRNA therapeutics company RinuaGene, has been approved for clinical study in cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) associated with human papillomavirus (HPV) 16 and/or…
-
Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study
•
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from the open-label, randomized Phase III SURMOUNT-5 study. The study assessed the weight loss effects of Zepbound (tirzepatide) compared to Wegovy (semaglutide) in adult patients with obesity or overweight, who have at least one weight-related medical…
-
Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer
•
Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track designation from the US Food and Drug Administration (FDA) for its bispecific antibody (bsAb) PT217. This designation is specifically for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). Earlier…
-
CGeneTech’s Cetagliptin Receives NMPA Approval for Type 2 Diabetes Treatment in China
•
The National Medical Products Administration (NMPA) in China has indicated on its website that CGeneTech (Suzhou, China) Co., Ltd.’s Category 1 drug, cetagliptin, has been granted marketing approval. This DPP-4 inhibitor is intended to improve blood sugar control in adult patients with type 2 diabetes (T2D). Phase III Clinical Trial…
-
Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment
•
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed drug, Leqembi (lecanemab), a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, has been approved by the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico. This approval marks another milestone in the treatment…
-
Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC
•
Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National Medical Products Administration (NMPA) to proceed with a second Phase III study for its antibody drug conjugate (ADC), ESG401. The study will focus on unresectable locally advanced, recurrent, or metastatic PD-L1 negative triple negative breast…
